clinical trial · NCT04314934
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
Alzheimer DiseaseANAVEX2-73
brief summary
This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.
started
Oct 10, 2019
primary completion
Jun 14, 2024
completion
Jun 14, 2024
last updated
Aug 12, 2024
detailed description
This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.
official title
Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol